CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy: Expert Opinion on Biological Therapy: Vol 7, No 8 Murad YM, Clay TM, Lyerly HK, Morse MA (2007) CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol ....
We now report that, similar to the depletion of regulatory T cells (Treg) using anti-CD25, paclitaxel increased the anti-tumor effect of the TLR9 agonist PF-3512676 in a CD8 + T cell-dependent fashion. Paclitaxel treatment decreased Treg numbers in a TLR4-independent fashion, and ...
Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor-9 agonist, are targeted immune modulators that elicit durable single-agent antitumour activity in advanced cancer. Methods: To determine the maximum tolerated dose (MTD) of these ...
FULL PAPER British Journal of Cancer (2013) 108, 1998–2004 | doi: 10.1038/bjc.2013.227 Keywords: melanoma; advanced solid tumours; combination immunotherapy; targeted immune modulator; tremelimumab; PF-3512676 Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients ...